Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 208

1.

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.

Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, Mohapi L, Short W, Crauwels H, Vanveggel S, Boven K.

HIV Med. 2012 Aug;13(7):406-15. doi: 10.1111/j.1468-1293.2012.00991.x. Epub 2012 Mar 14.

PMID:
22416849
[PubMed - indexed for MEDLINE]
2.

Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.

Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S, Stevens M, Rimsky L, Thorpe D, Bosse M, White K, Zhong L, DeMorin J, Chuck SK.

AIDS Patient Care STDS. 2014 Apr;28(4):168-75. doi: 10.1089/apc.2013.0310. Epub 2014 Mar 24.

PMID:
24660840
[PubMed - indexed for MEDLINE]
3.

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO study group.

Lancet. 2011 Jul 16;378(9787):238-46. doi: 10.1016/S0140-6736(11)60936-7.

PMID:
21763936
[PubMed - indexed for MEDLINE]
4.

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K; THRIVE study group.

Lancet. 2011 Jul 16;378(9787):229-37. doi: 10.1016/S0140-6736(11)60983-5.

PMID:
21763935
[PubMed - indexed for MEDLINE]
5.

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.

HIV Clin Trials. 2013 May-Jun;14(3):81-91. doi: 10.1310/hct1403-81.

PMID:
23835510
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.

Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K, Crauwels H, Lefebvre E, Rimsky LT, Vanveggel S, Williams P, Boven K; ECHO Study Group; THRIVE Study Group.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):33-42. doi: 10.1097/QAI.0b013e31824d006e.

PMID:
22343174
[PubMed - indexed for MEDLINE]
7.

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.

Wilkin A, Pozniak AL, Morales-Ramirez J, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group.

AIDS Res Hum Retroviruses. 2012 May;28(5):437-46. doi: 10.1089/AID.2011.0050. Epub 2011 Oct 17.

PMID:
21902621
[PubMed - indexed for MEDLINE]
8.

Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.

Molina JM, Clumeck N, Redant K, Rimsky L, Vanveggel S, Stevens M; ECHO Study Group; THRIVE Study Group.

AIDS. 2013 Mar 27;27(6):889-97. doi: 10.1097/QAD.0b013e32835e1554.

PMID:
23276806
[PubMed - indexed for MEDLINE]
9.

Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.

Ruane P, Lang J, DeJesus E, Berger DS, Dretler R, Rodriguez A, Ward DJ, Lim ML, Liao Q, Reddy S, Clair MS, Vila T, Shaefer MS.

HIV Clin Trials. 2006 Sep-Oct;7(5):229-36.

PMID:
17162316
[PubMed - indexed for MEDLINE]
Free Article
10.

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

Vingerhoets J, Rimsky L, Van Eygen V, Nijs S, Vanveggel S, Boven K, Picchio G.

Antivir Ther. 2013;18(2):253-6. doi: 10.3851/IMP2358. Epub 2012 Sep 6.

PMID:
22951490
[PubMed - indexed for MEDLINE]
11.

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.

Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink HJ, Li T, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K; ECHO, THRIVE study groups.

AIDS. 2013 Mar 27;27(6):939-50. doi: 10.1097/QAD.0b013e32835cee6e.

PMID:
23211772
[PubMed - indexed for MEDLINE]
12.

Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.

Molina JM, Clumeck N, Orkin C, Rimsky LT, Vanveggel S, Stevens M; ECHO and THRIVE Study Groups.

HIV Med. 2014 Jan;15(1):57-62. doi: 10.1111/hiv.12071. Epub 2013 Aug 28.

PMID:
23980523
[PubMed - indexed for MEDLINE]
13.

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):49-57. doi: 10.1097/QAI.0b013e3181dd911e.

PMID:
20431394
[PubMed - indexed for MEDLINE]
14.

Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.

Mills AM, Cohen C, Dejesus E, Brinson C, Williams S, Yale KL, Ramanathan S, Wang MH, White K, Chuck SK, Cheng AK.

HIV Clin Trials. 2013 Sep-Oct;14(5):216-23. doi: 10.1310/hct1405-216.

PMID:
24144898
[PubMed - indexed for MEDLINE]
15.

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.

AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.

PMID:
21412057
[PubMed - indexed for MEDLINE]
16.

Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.

Ruane PJ, Parenti DM, Margolis DM, Shepp DH, Babinchak TJ, Van Kempen AS, Kauf TL, Danehower SA, Yau L, Hessenthaler SM, Goodwin D, Hernandez JE; COL30336 Study Team.

HIV Clin Trials. 2003 Jul-Aug;4(4):231-43.

PMID:
12916008
[PubMed - indexed for MEDLINE]
17.

Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.

Mills AM, Antinori A, Clotet B, Fourie J, Herrera G, Hicks C, Madruga JV, Vanveggel S, Stevens M, Boven K; ECHO and THRIVE study groups.

HIV Med. 2013 Aug;14(7):391-400. doi: 10.1111/hiv.12012. Epub 2013 Jan 9.

PMID:
23298380
[PubMed - indexed for MEDLINE]
18.

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.

Nelson M, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P, Li T, Tebas P, Stevens M, Buelens A, Vanveggel S, Boven K; ECHO and THRIVE Study Groups.

J Antimicrob Chemother. 2012 Aug;67(8):2020-8. doi: 10.1093/jac/dks130. Epub 2012 Apr 24.

PMID:
22532465
[PubMed - indexed for MEDLINE]
Free Article
19.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; AIDS Clinical Trials Group Study A5202 Team.

J Infect Dis. 2011 Oct 15;204(8):1191-201. doi: 10.1093/infdis/jir505.

PMID:
21917892
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.

Markowitz M, Hill-Zabala C, Lang J, DeJesus E, Liao Q, Lanier ER, Davis EA, Shaefer M; ESS40013 Study Team.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):257-64.

PMID:
15980684
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk